The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer

Daniela Di Lisi,Cristina Madaudo,Denise Cristiana Faro,Ludovico Rossetto,Oreste Fabio Triolo,Valentina Losi,Alfredo Ruggero Galassi,Ines Paola Monte,Giuseppina Novo

DOI: https://doi.org/10.2459/jcm.0000000000001589

IF: 2.43

2024-02-04

Journal of Cardiovascular Medicine

Abstract:The 2022 ESC Guidelines on Cardio-Oncology recommend baseline cardiovascular risk stratification before starting anticancer drugs, using the new risk assessment tools proposed by the Heart Failure Association (HFA) and the International Cardio-Oncology Society (ICOS).

cardiac & cardiovascular systems